First study on the efficiency of 99mTc-rituximab for sentinel lymph node mapping and biopsy in oral squamous cell carcinoma

IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Yang Liu, Fei Wang, Yufei Song, Xiaochuan Zhou, Xin Zhou, Changzhi Du, Yan Cui, Yitong Liu, Nan Li
{"title":"First study on the efficiency of 99mTc-rituximab for sentinel lymph node mapping and biopsy in oral squamous cell carcinoma","authors":"Yang Liu,&nbsp;Fei Wang,&nbsp;Yufei Song,&nbsp;Xiaochuan Zhou,&nbsp;Xin Zhou,&nbsp;Changzhi Du,&nbsp;Yan Cui,&nbsp;Yitong Liu,&nbsp;Nan Li","doi":"10.1007/s12149-024-02012-5","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To explore the clinical efficiency of using the sentinel lymph node (SLN) imaging agent <sup>99m</sup>Tc-rituximab for lymphoscintigraphy and SLN biopsy (SLNB) in oral squamous cell carcinoma (OSCC) patients.</p><h3>Methods</h3><p>A retrospective study was conducted on 23 patients with OSCC who underwent <sup>99m</sup>Tc-rituximab lymphoscintigraphy and SLNB. The cohort comprised 16 men (69.6%) and 7 women (30.4%) with a median age of 64.0 years (range: 33–90 years). All patients received a preoperative peritumoral injection of <sup>99m</sup>Tc-rituximab. The SLN detection rates (SDRs) of SLN imaging and SLNB were analyzed. The localizations of SLNs were counted. Patients were followed up after surgery. Differences were considered significant for a <i>p</i>-value of less than 0.05.</p><h3>Results</h3><p>The SDRs of lymphoscintigraphy and SLNB were 91.3% (21/23) and 100.0% (23/23), respectively. The SDRs of lymphoscintigraphy for patients in pathological stages I/II and III/IVa were 100.0% (15/15) and 75.0% (6/8), respectively. Among the 2 patients with negative imaging results, both were stage IVa and both had SLN metastasis. The SLNs were located in levels Ib, IIa, IIb, III, and IV, accounting for 45.0% (18/40), 40.0% (16/40), 10.0% (4/40), 2.5% (1/40), and 2.5% (1/40), respectively. The median follow-up duration was 32.0 months (range: 13.0–68.0 months). During follow-up, none of the 23 patients (100.0%) showed lymph node (LN) metastasis. As a result, the sensitivity, negative predictive value (NPV), and accuracy were all 100.0%.</p><h3>Conclusions</h3><p>The application of <sup>99m</sup>Tc-rituximab for SLN imaging and SLNB in OSCC patients demonstrated high detection rates and accuracy, holding significant clinical value.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 4","pages":"380 - 387"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-024-02012-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

To explore the clinical efficiency of using the sentinel lymph node (SLN) imaging agent 99mTc-rituximab for lymphoscintigraphy and SLN biopsy (SLNB) in oral squamous cell carcinoma (OSCC) patients.

Methods

A retrospective study was conducted on 23 patients with OSCC who underwent 99mTc-rituximab lymphoscintigraphy and SLNB. The cohort comprised 16 men (69.6%) and 7 women (30.4%) with a median age of 64.0 years (range: 33–90 years). All patients received a preoperative peritumoral injection of 99mTc-rituximab. The SLN detection rates (SDRs) of SLN imaging and SLNB were analyzed. The localizations of SLNs were counted. Patients were followed up after surgery. Differences were considered significant for a p-value of less than 0.05.

Results

The SDRs of lymphoscintigraphy and SLNB were 91.3% (21/23) and 100.0% (23/23), respectively. The SDRs of lymphoscintigraphy for patients in pathological stages I/II and III/IVa were 100.0% (15/15) and 75.0% (6/8), respectively. Among the 2 patients with negative imaging results, both were stage IVa and both had SLN metastasis. The SLNs were located in levels Ib, IIa, IIb, III, and IV, accounting for 45.0% (18/40), 40.0% (16/40), 10.0% (4/40), 2.5% (1/40), and 2.5% (1/40), respectively. The median follow-up duration was 32.0 months (range: 13.0–68.0 months). During follow-up, none of the 23 patients (100.0%) showed lymph node (LN) metastasis. As a result, the sensitivity, negative predictive value (NPV), and accuracy were all 100.0%.

Conclusions

The application of 99mTc-rituximab for SLN imaging and SLNB in OSCC patients demonstrated high detection rates and accuracy, holding significant clinical value.

99mtc -利妥昔单抗用于口腔鳞状细胞癌前哨淋巴结定位和活检效率的首次研究。
目的:探讨口腔鳞状细胞癌(OSCC)患者前哨淋巴结(SLN)显像剂99mtc -利妥昔单抗(rituximab)淋巴显像及SLN活检(SLNB)的临床疗效。方法:对23例行99mtc -利妥昔单抗淋巴显像和SLNB的OSCC患者进行回顾性研究。该队列包括16名男性(69.6%)和7名女性(30.4%),中位年龄为64.0岁(范围:33-90岁)。所有患者术前均接受肿瘤周围注射99mtc -利妥昔单抗。分析SLN成像和SLNB的SLN检出率(SDRs)。统计sln的定位情况。术后随访。当p值小于0.05时,认为差异显著。结果:淋巴显像和SLNB的sdr分别为91.3%(21/23)和100.0%(23/23)。病理分期I/II期和III/IVa期患者淋巴显影的drs分别为100.0%(15/15)和75.0%(6/8)。2例影像学结果阴性的患者均为IVa期,均有SLN转移。sln分布在Ib、IIa、IIb、III和IV层,分别占45.0%(18/40)、40.0%(16/40)、10.0%(4/40)、2.5%(1/40)和2.5%(1/40)。中位随访时间为32.0个月(范围:13.0 ~ 68.0个月)。随访期间,23例患者均无淋巴结转移(100.0%)。结果表明,敏感性、阴性预测值(NPV)和准确率均为100.0%。结论:99mtc -利妥昔单抗在OSCC患者SLN成像和SLNB中的应用具有较高的检出率和准确性,具有重要的临床价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Nuclear Medicine
Annals of Nuclear Medicine 医学-核医学
CiteScore
4.90
自引率
7.70%
发文量
111
审稿时长
4-8 weeks
期刊介绍: Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信